588 related articles for article (PubMed ID: 22578254)
1. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.
Kometer M; Schmidt A; Bachmann R; Studerus E; Seifritz E; Vollenweider FX
Biol Psychiatry; 2012 Dec; 72(11):898-906. PubMed ID: 22578254
[TBL] [Abstract][Full Text] [Related]
2. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.
Kometer M; Schmidt A; Jäncke L; Vollenweider FX
J Neurosci; 2013 Jun; 33(25):10544-51. PubMed ID: 23785166
[TBL] [Abstract][Full Text] [Related]
3. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.
Schmidt A; Kometer M; Bachmann R; Seifritz E; Vollenweider F
Psychopharmacology (Berl); 2013 Jan; 225(1):227-39. PubMed ID: 22836372
[TBL] [Abstract][Full Text] [Related]
4. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.
Carter OL; Hasler F; Pettigrew JD; Wallis GM; Liu GB; Vollenweider FX
Psychopharmacology (Berl); 2007 Dec; 195(3):415-24. PubMed ID: 17874073
[TBL] [Abstract][Full Text] [Related]
5. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.
Quednow BB; Kometer M; Geyer MA; Vollenweider FX
Neuropsychopharmacology; 2012 Feb; 37(3):630-40. PubMed ID: 21956447
[TBL] [Abstract][Full Text] [Related]
6. Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.
Bernasconi F; Schmidt A; Pokorny T; Kometer M; Seifritz E; Vollenweider FX
Cereb Cortex; 2014 Dec; 24(12):3221-31. PubMed ID: 23861318
[TBL] [Abstract][Full Text] [Related]
7. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations.
Kometer M; Cahn BR; Andel D; Carter OL; Vollenweider FX
Biol Psychiatry; 2011 Mar; 69(5):399-406. PubMed ID: 21126732
[TBL] [Abstract][Full Text] [Related]
8. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.
Carter OL; Burr DC; Pettigrew JD; Wallis GM; Hasler F; Vollenweider FX
J Cogn Neurosci; 2005 Oct; 17(10):1497-508. PubMed ID: 16269092
[TBL] [Abstract][Full Text] [Related]
9. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
[TBL] [Abstract][Full Text] [Related]
10. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.
Grimm O; Kraehenmann R; Preller KH; Seifritz E; Vollenweider FX
Eur Neuropsychopharmacol; 2018 Jun; 28(6):691-700. PubMed ID: 29703645
[TBL] [Abstract][Full Text] [Related]
11. Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.
Bravermanová A; Viktorinová M; Tylš F; Novák T; Androvičová R; Korčák J; Horáček J; Balíková M; Griškova-Bulanova I; Danielová D; Vlček P; Mohr P; Brunovský M; Koudelka V; Páleníček T
Psychopharmacology (Berl); 2018 Feb; 235(2):491-503. PubMed ID: 29302713
[TBL] [Abstract][Full Text] [Related]
12. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX
Eur Neuropsychopharmacol; 2016 Apr; 26(4):756-66. PubMed ID: 26875114
[TBL] [Abstract][Full Text] [Related]
13. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.
Stroud JB; Freeman TP; Leech R; Hindocha C; Lawn W; Nutt DJ; Curran HV; Carhart-Harris RL
Psychopharmacology (Berl); 2018 Feb; 235(2):459-466. PubMed ID: 29085980
[TBL] [Abstract][Full Text] [Related]
14. MDMA-induced indifference to negative sounds is mediated by the 5-HT
Kuypers KPC; de la Torre R; Farre M; Pizarro N; Xicota L; Ramaekers JG
Psychopharmacology (Berl); 2018 Feb; 235(2):481-490. PubMed ID: 28735368
[TBL] [Abstract][Full Text] [Related]
15. Effect of Psilocybin on Empathy and Moral Decision-Making.
Pokorny T; Preller KH; Kometer M; Dziobek I; Vollenweider FX
Int J Neuropsychopharmacol; 2017 Sep; 20(9):747-757. PubMed ID: 28637246
[TBL] [Abstract][Full Text] [Related]
16. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.
Liechti ME; Saur MR; Gamma A; Hell D; Vollenweider FX
Neuropsychopharmacology; 2000 Oct; 23(4):396-404. PubMed ID: 10989266
[TBL] [Abstract][Full Text] [Related]
17. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.
Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; Weston N; Malievskaia E; Young AH
J Psychopharmacol; 2022 Jan; 36(1):114-125. PubMed ID: 35090363
[TBL] [Abstract][Full Text] [Related]
18. Effects of psilocybin on time perception and temporal control of behaviour in humans.
Wittmann M; Carter O; Hasler F; Cahn BR; Grimberg U; Spring P; Hell D; Flohr H; Vollenweider FX
J Psychopharmacol; 2007 Jan; 21(1):50-64. PubMed ID: 16714323
[TBL] [Abstract][Full Text] [Related]
19. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.
Umbricht D; Vollenweider FX; Schmid L; Grübel C; Skrabo A; Huber T; Koller R
Neuropsychopharmacology; 2003 Jan; 28(1):170-81. PubMed ID: 12496954
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of serotonin enhances pleasant and suppresses unpleasant cortical electrophysiological responses to visual emotional stimuli in humans.
Kemp AH; Gray MA; Silberstein RB; Armstrong SM; Nathan PJ
Neuroimage; 2004 Jul; 22(3):1084-96. PubMed ID: 15219580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
